BMC medicine · 2026
PCDSOS: a novel clinical predictive tool for screening primary ciliary dyskinesia in adult bronchiectasis patients-a multicenter derivation and external validation study.
СтатьяМногоцентровое исследованиеВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Wangji, Wang Lin, Chen Qiaoling, Wang Yaqi, Pang Haiyu, Guo Anhui, Wu Aohua, Liu Xueqi, Dai Jinrong, Meng Shuzhen, Wang Rongchun, Yang Danhui, Liu Yaping, Zhu Weiguo, Xu Kai-Feng, Zhang Xue, Luo Hong, Tian Xinlun
Аннотация
BACKGROUND: Primary ciliary dyskinesia (PCD) is a rare but underdiagnosed genetic cause of adult bronchiectasis, with current predictive tools (e.g., PICADAR, NA-CDCF) primarily validated in children and lacking adult-specific predictors (e.g., subfertility). This study aimed to develop and validate a practical tool (PCDSOS) for PCD screening in adult bronchiectasis.
METHODS: Derivation group (n = 287) from Peking Union Medical College Hospital (2013-2025) and validation group (n = 107) from The Second Xiangya Hospital (2016-2024) were included. All patients completed ≥ 1 PCD diagnostic test (nasal nitric oxide, whole-exome sequencing, transmission electron microscopy, or high-speed video microscopy analysis). Logistic regression was used to develop PCDSOS, with performance assessed by AUC, calibration curve, and decision curve analysis.
RESULTS: Existing tools showed reduced accuracy in adults (AUC: 0.76-0.85 vs. 0.84-0.98 in original studies). PCDSOS included 6 predictors: pulmonary atelectasis/lobectomy in middle lobe/lingula (P, 2 points), neonatal chest symptoms (C, 2 points), organ laterality defects (D, 5 points), chronic sinusitis (S, 2 points), chronic otitis media/hearing loss from childhood (O, 1 point), and subfertility (S, 1 point). At cutoff = 3, PCDSOS had sensitivity 0.86, specificity 0.76 (derivation cohort, AUC = 0.90) and sensitivity 0.90, specificity 0.67 (validation cohort, AUC = 0.92). A free web-based version of PCDSOS for automated scoring is available to facilitate clinical application.
CONCLUSIONS: PCDSOS outperforms existing tools in adult bronchiectasis, providing a cost-effective screening strategy to identify patients requiring further PCD diagnostic testing-critical for preventing irreversible lung damage and guiding genetic counseling.
METHODS: Derivation group (n = 287) from Peking Union Medical College Hospital (2013-2025) and validation group (n = 107) from The Second Xiangya Hospital (2016-2024) were included. All patients completed ≥ 1 PCD diagnostic test (nasal nitric oxide, whole-exome sequencing, transmission electron microscopy, or high-speed video microscopy analysis). Logistic regression was used to develop PCDSOS, with performance assessed by AUC, calibration curve, and decision curve analysis.
RESULTS: Existing tools showed reduced accuracy in adults (AUC: 0.76-0.85 vs. 0.84-0.98 in original studies). PCDSOS included 6 predictors: pulmonary atelectasis/lobectomy in middle lobe/lingula (P, 2 points), neonatal chest symptoms (C, 2 points), organ laterality defects (D, 5 points), chronic sinusitis (S, 2 points), chronic otitis media/hearing loss from childhood (O, 1 point), and subfertility (S, 1 point). At cutoff = 3, PCDSOS had sensitivity 0.86, specificity 0.76 (derivation cohort, AUC = 0.90) and sensitivity 0.90, specificity 0.67 (validation cohort, AUC = 0.92). A free web-based version of PCDSOS for automated scoring is available to facilitate clinical application.
CONCLUSIONS: PCDSOS outperforms existing tools in adult bronchiectasis, providing a cost-effective screening strategy to identify patients requiring further PCD diagnostic testing-critical for preventing irreversible lung damage and guiding genetic counseling.